Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI)

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services to enable the development of drugs, therapeutics vaccines and diagnostics and support research on human disease.

The company generates revenue by selling complex nucleic acids for therapeutic vaccine and diagnostic applications custom enzymes for research and diagnostic use and antibody based solutions to detect impurities during biopharmaceutical production serving biopharmaceutical companies emerging biotech firms life science research organizations academic research institutions and diagnostics companies.

The company operates through the following segments.

• TriLink provides nucleic acid products and related services including mRNA oligonucleotides CleanCap mRNA capping technology ModTm polyA tail modification synthesis inputs nucleoside triphosphates specialty enzymes and mRNA manufacturing services supporting research use only and GMP materials for preclinical clinical and commercial applications.

• Cygnus offers biologics safety testing products and services such as host cell protein ELISA kits impurity detection assays viral clearance prediction tools ancillary reagents and custom analytical services used to detect process related impurities in monoclonal antibodies recombinant proteins vaccines and cell and gene therapies.

Maravai LifeSciences Holdings, Inc. holds a strong position in the life sciences supply chain due to its proprietary technologies like CleanCap and ModTm vertical integration and extensive patent portfolio while competing with chemistry companies custom oligonucleotide manufacturers mRNA focused biotech firms CDMOs and impurity detection kit providers.

The company serves a diverse customer base that includes biopharmaceutical companies emerging biotech firms life science research organizations academic institutions and diagnostics companies without disclosing specific client names.